SEC Tracker
Get the app
GNLX · XBRL financial data

GENELUX financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (GNLX's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers0*0*80*0*0*———year only——
Research and development2,8194,160*4,0104,4174,0516,520*4,6984,7584,7415,654*5,7786,508
General and administrative2,4882,841*4,1132,4752,8903,228*3,1183,0343,4533,766*3,3933,137
Total operating expenses5,3077,001*8,1236,8926,9419,748*7,8167,7928,1949,420*9,1719,645
Operating income (loss)(5,307)(7,001)*(8,115)(6,892)(6,941)(9,748)*(7,816)(7,792)(8,194)(9,412)*(9,171)(9,645)
Interest income4240*265316474(355)*184224175128*173127
Interest expense—6*——————————
Net income (loss)(5,345)(6,767)*(7,850)(6,576)(6,467)(8,976)*(7,492)(7,456)(7,950)(9,247)*(8,928)(9,471)
Earnings per share, basic USD per share(0.20)(0.25)*(0.29)(0.22)(0.19)(0.26)*(0.21)(0.20)(0.21)(0.24)*(0.20)(0.21)
Earnings per share, diluted USD per share(0.20)(0.25)*(0.29)(0.22)(0.19)(0.26)*(0.21)(0.20)(0.21)(0.24)*(0.20)(0.21)
Weighted average shares, basic thousands of shares26,21026,765*26,85029,68934,53234,662*34,92637,94637,89337,900*44,15144,959
Weighted average shares, diluted thousands of shares26,21026,765*26,85029,68934,53234,662*34,92637,94637,89337,900*44,15144,959

Balance sheet

CSV

Fiscal quarters (GNLX's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents29,8699,4184,0617,8586,1028,56516,2066,5464,6925,3339,2739,184
Short-term investments—13,77315,56625,77827,95522,33018,89621,42616,223—16,9009,500
Prepaid and other current assets1,3101,0121,5771,2341,9106538431,263637535545474
Total current assets31,17924,20321,20434,87035,96731,54835,94529,23521,55215,13026,75419,144
Property and equipment, net1,0221,1701,1161,3061,2781,3161,2871,3391,7942,1703,0814,603
Right-of-use asset1,7792,4282,2642,0981,9301,7601,6801,6001,5181,5832,3932,312
Total assets34,07227,89324,67645,17940,27034,71638,98532,24724,98719,02732,37226,205
Total current liabilities8,7556,5547,8055,8035,5556,9037,6896,9885,1266,2257,2727,998
Lease liability, non-current1,2891,8661,7871,7071,6241,5391,4501,3611,2701,2582,1792,094
Total liabilities10,0448,4209,5927,5107,1798,4429,1398,3496,3967,4839,45110,092
Accumulated deficit(214,757)(221,524)(229,374)(235,950)(242,417)(251,393)(258,885)(266,341)(274,291)(283,538)(292,466)(301,937)
Total stockholders' equity24,02819,47315,08437,66933,09126,27429,84623,89818,59111,54422,92116,113
Total liabilities and equity34,07227,89324,67645,17940,27034,71638,98532,24724,98719,02732,37226,205
Common shares outstanding (cover page) thousands of shares26,71826,86526,99734,53534,53834,60437,73537,77338,05244,80644,84045,245

Cash flows

CSV

Fiscal quarters (GNLX's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(5,345)(6,767)*(7,850)(6,576)(6,467)(8,976)*(7,492)(7,456)(7,950)(9,247)*(8,928)(9,471)
Stock-based compensation515*1,533*1,4891,298*1,521*1,430*1,4231,290*1,623*1,535*1,394—
Net cash from operating activities(3,357)*(6,910)*(4,354)(6,824)*(5,748)*(4,302)*(5,435)(7,059)*(6,575)*(6,199)*(6,059)(6,444)*
Purchases of property and equipment277*243*30228*27*96*30115*517*436*9211,532*
Net cash from investing activities(277)*(13,942)*(1,691)(17,106)*3,992*6,674*3,509(2,653)*4,721*6,564*(8,539)5,968*
Proceeds from issuing common stock3,500*0*——0*15*9,5530*0*0*18,525340*
Net cash from financing activities6,363*401*68827,727*0*91*9,56752*0*276*18,538387*
Net change in cash2,729*(20,451)*(5,357)3,797*(1,756)*2,463*7,641(9,660)*(1,854)*641*3,940(89)*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
GENELUX9,184not reported(6,444)*45.2M2.9 quarters 10-QJun 30, 2026
Filana Therapeutics46,990not reported(6,094)*50.3M7.5 quarters 10-QSep 30, 2026
Anixa Biosciences1,398not reported(1,770)*34.8M6.8 quarters 10-QJul 31, 2026
Entera Bio11,3090(3,464)*173.1M3.3 quarters 10-QJun 30, 2026
Larimar Therapeutics92,687not reported(44,030)*103.9M3.5 quarters 10-QJun 30, 2026
Immunic155,098not reported(30,998)*13.6M5.0 quarters 10-QJun 30, 2026
DiaMedica Therapeutics5,129not reported(8,114)*53.9M5.4 quarters 10-QJun 30, 2026
Coherus Oncology82,923not reported(62,090)*154.5M1.7 quarters 10-QJun 30, 2026
Elicio Therapeutics30,900not reported(10,364)*28.3M3.1 quarters 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched . The filing on SEC.gov is the record.